Management of cystic echinococcosis in British Columbia: outcomes and suggestions to improve guideline adherence Authors: Nicola Colucci, Anastasios D. Giannou, Suefay Harumi Liu, Calvin Ka-Fung Lo, Mohammed Al-Abri, Catherine A. Hogan, Katherine Plewes, Michael S. Bleszynski, Maja Segedi Published: 2026 ABSTRACT SummaryCystic echinococcosis (CE) is rare in Canada but continues to appear sporadically, sometimes in patients who have not travelled to endemic regions. Since 2010, World Health Organization (WHO) guidelines have emphasized stage-specific management, yet the extent to which this approach is applied in Canadian practice is uncertain. We reviewed 41 cases of CE managed in British Columbia between 2010 and 2022; only about two-thirds received treatment aligned with WHO guidance. The primary gap was in radiology reporting, which frequently documented cyst size but omitted the staging details essential for surgical decision-making. Although outcomes were generally favourable, the lack of standardized pathways led to unnecessary clinical variation. Structured radiology reporting, multidisciplinary oversight and provincial collaboration remain essential to ensure consistent, evidence-based care, especially for rare diseases where experience is limited. Cystic echinococcosis (CE) is an uncommon diagnosis in Canada, yet its rarity may contribute to delayed diagnosis and suboptimal management, with potentially serious consequences. Between 2000 and 2020, 806 cases of echinococcosis were reported nationally, resulting in a mean annual incidence of 1.3 per million population. Regional differences were noted, with rates as high as 9 per million in the territories and an upward trend reaching 2.4 per million in Alberta.1 Most surgeons in Canada will encounter only a handful of cases during their career, with a somewhat greater likelihood in higher-incidence regions. The rarity of CE poses a practical challenge, as management can become inconsistent in the absence of defined pathways, even in well-resourced health systems. International guidance from the World Health Organization (WHO) Informal Working Group on Echinococcosis (IWGE) has long stressed that management of CE should be guided by cyst stage. The 2010 WHO-IWGE consensus formalized the ultrasound-based CE 1 to CE 5 classification and linked each stage to specific interventions2 (Figure 1). We identified and reviewed 41 cases of CE managed in British Columbia between 2010 and 2022; stage-specific management was already the recommended standard throughout our study period. Of the 39 patients whose cysts could be staged retrospectively, only about two-thirds received care aligned with WHO guidance (Table 1). The shortfall often originated from radiology reporting: although imaging reliably documented cyst size and location, staging description was often missing. The WHO-IWGE classification was developed for ultrasonography, which remains the reference modality for identifying the internal morphologic features of the hydatid cysts. In practice, many patients underwent computed tomography (CT) as first-line imaging, and ultrasonography or magnetic resonance imaging (MRI) were not always performed subsequently to refine staging. In addition, radiology reports did not systematically include WHO stage; without this information, clinicians were left to make management decisions without the most critical determinant of therapy. Outcomes among patients managed outside guideline recommendations were generally favourable: operative cases recovered without overt complications or recurrence, whereas percutaneous treatments had only sporadic recurrence. Most adverse events were medical; albendazole-related hepatotoxicity was most common. These results should not be interpreted as a reason to disregard guidelines, but they show that adherence to stage-based guidance remains the safest way to standardize decision-making and minimize risks associated with clinical misjudgment. The central lesson for surgeons is that management of rare diseases requires structured approaches to ensure consistency of care. Treatment planning should always be informed by cyst stage, and perioperative anthelmintic therapy must be coordinated with the planned procedure. Operating outside recommended staging indications exposes patients to unnecessary risks of rupture, spillage, and recurrence. Technical success in this series should be seen as the exception that proves the rule: good operative technique matters, but it does not replace correct indication. Cystic echinococcosis differs from many routine surgical conditions: success depends on knowing when to operate, when to defer, and when to prefer medical or percutaneous approaches. These decisions are best made in multidisciplinary forums. In our experience, infectious disease specialists and radiologists were often involved, yet management of CE still varied. Formalized multidisciplinary oversight would likely narrow this variation and ensure that patients are not exposed to interventions inconsistent with best practice. This review also highlights the limits of single-centre learning: no hospital will routinely accumulate enough cases to build institutional expertise, therefore clinical divergence is unsurprising. A few practical steps could substantially reduce such variation. Radiology reports for suspected CE should include a mandatory WHO staging field, and CT findings suspicious for hydatid disease should trigger focused ultrasonography or MRI when staging is uncertain. Clinicians should keep CE in the differential diagnosis for solitary complex hepatic cysts, even in patients who have not travelled to highly endemic regions. Because expertise in these uncommon pathologies is dispersed, multidisciplinary discussion involving surgery, radiology, and infectious diseases specialists is a practical safeguard that increases the likelihood that staging is confirmed and that management aligns with guidelines. These measures are easy to pilot at a provincial level and could be scaled nationally if effective. A national registry, similar to the European Register of Cystic Echinococcosis,3 remains an ambitious long-term goal to document outcomes in a systematic way and create a Canadian-specific body of evidence to integrate international recommendations. However, implementing provincial pilot networks that connect referral centres, share imaging and pathology, and allow rapid teleconferenced multidisciplinary review remains a more achievable goal. Such collaboration could also support genotyping of archived specimens to clarify whether locally acquired cases are caused by sylvatic Echinococcus canadensis strains,4 which may behave differently from imported E. granulosus or the emerging European-type E. multilocularis strains.1 Understanding these differences could ultimately refine surgical and medical approaches within our health systems. Our review underscores that access to advanced imaging, interventional radiology and specialist surgery is not enough to guarantee evidence-based care. For surgeons encountering CE, the priority is recognizing that treatment is strictly stage-dependent, as defined by international guidelines. This necessitates both insisting on explicit cyst staging in radiology reports and seeking multidisciplinary consensus before intervention. By bridging the gap between guidelines and practice, we can offer patients consistent and evidence-based care, even for a disease most of us will encounter only once or twice in our careers.